Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Rigosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 0.81 |
| ▸ | NQO2 | P16083 | 1/20 | 0.81 |
| ▸ | FECH | P22830 | 1/20 | 0.81 |
| ▸ | CLK3 | P49761 | 1/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.78 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.78 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.78 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.78 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.78 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.78 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.78 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.78 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rigosertib SCHEMBL4726480 | 1.00 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498729 | 1.00 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL29397572 | 0.90 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498623 | 0.90 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL498448 | 0.90 | PLK1 (0.84) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL498447 | 0.90 | PLK1 (0.84) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498624 | 0.90 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498728 | 0.89 | PLK1 (0.98) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498730 | 0.89 | PLK1 (0.98) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL15835693 | 0.85 | PLK1 (0.77) | PLK1METNQO2FECHCLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022144780-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS | NATIONAL CANCER CENTER (JP) | 2022-07-07 | — | — | WO | claimed |
| CN-122029161-A | Crystalline forms of PI3K inhibitors and uses thereof | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | SECURA BIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-12545896-B2 | Growth inhibitor | Orizuru Therapeutics, Inc. (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-07 | — | — | US | disclosed |
| EP-4611748-A1 | COMBINATION THERAPY FOR TREATING CANCER | Scorpion Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250262298-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-21 | — | — | US | disclosed |
| EP-4396189-B1 | IRON-ACTIVABLE NITROGEN-CONTAINING DERIVATIVES OF SALINOMYCIN AND NARASIN, SYNTHESIS AND USE FOR THE TREATMENT OF CANCERS | CENTRE NAT RECH SCIENT (FR) | 2025-08-13 | — | — | EP | disclosed |
| CN-114729004-A | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022144780-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS | NATIONAL CANCER CENTER (JP) | 2022-07-07 | — | — | WO | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-11351209-B2 | Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-4006037-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| CN-114423767-A | Artemisinin derivative N-heterocyclic carbene gold (I) hybrid compound | 法国国家科学研究中心 | 2022-04-29 | — | — | CN | disclosed |
| US-20220089595-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-24 | — | — | US | disclosed |
| EP-3241846-B1 | B7 FAMILY MEMBER ZB7H6 AND RELATED COMPOSITIONS AND METHODS | ZYMOGENETICS INC (US) | 2022-02-23 | — | — | EP | disclosed |
| WO-2022019920-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | VERASTEM, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089595-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | PLK1 4739/4885MET 1995/4885NQO2 2237/4885 |
| US-11351209-B2 | Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer | PI4KA, PIK3CA, PIK3R4 | PLK1 75/4885MET 1596/4885NQO2 3867/4885 |
| US-20250262298-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | PLK1 238/4885MET 4562/4885NQO2 925/4885 |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3R5, PIK3R4, PIK3CD | PLK1 283/4885MET 1508/4885NQO2 2708/4885 |
| US-12435063-B2 | Nitrogen containing heterocycles as CDK12 inhibitors | CDK1, CDK12, CDK15 | PLK1 26/4885MET 2912/4885NQO2 679/4885 |
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | PLK1 49/4885MET 755/4885NQO2 1737/4885 |
| US-12545896-B2 | Growth inhibitor | IAPP, PLK4, IGF1R | PLK1 62/4885MET 167/4885NQO2 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.